Helixmith Co., Ltd
084990 | KO
Overview
Corporate Details
- ISIN(s):
- KR7084990001
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강서구 마곡중앙8로7길 21, 강서구
- Website:
- https://www.helixmith.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
No description available.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
You have of free filing views remaining.
Upgrade for unlimited access.
Bulk Actions:
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-09-18 00:00 |
Report Publication Announcement
기업설명회(IR)개최
|
Korean | 6.9 KB | ||
| 2025-08-14 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 1.9 MB | ||
| 2025-08-14 00:00 |
Interim / Quarterly Report
반기보고서 (2025.06)
|
Korean | 1.3 MB | ||
| 2025-07-09 00:00 |
AGM Information
임시주주총회결과
|
Korean | 6.1 KB | ||
| 2025-06-19 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 51.3 KB | ||
| 2025-06-18 00:00 |
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
|
Korean | 15.2 KB | ||
| 2025-06-18 00:00 |
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
|
Korean | 48.4 KB | ||
| 2025-05-16 00:00 |
Quarterly Report
[기재정정]분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-05-15 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 10.0 KB | ||
| 2025-05-15 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.1 MB | ||
| 2025-05-15 00:00 |
Pre-Annual General Meeting Information
주주명부폐쇄기간또는기준일설정
|
Korean | 5.7 KB | ||
| 2025-05-02 00:00 |
Legal Proceedings Report
소송등의판결ㆍ결정 (주주총회소집허가)
|
Korean | 6.2 KB | ||
| 2025-03-27 00:00 |
AGM Information
정기주주총회결과
|
Korean | 22.0 KB | ||
| 2025-03-27 00:00 |
Annual Report
[기재정정]사업보고서 (2024.12)
|
Korean | 1.9 MB | ||
| 2025-03-27 00:00 |
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 10.1 KB |
Automate Your Workflow. Get a real-time feed of all Helixmith Co., Ltd filings delivered via API.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
Unlock Full Financials for Helixmith Co., Ltd
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Helixmith Co., Ltd via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
Company
Country
Ticker
View
A leader in antisense technology, developing RNA-targeted drugs for neurology and cardiology.
United States of America
IONS
United States of America
IONS
Developing personalized T-cell immunotherapies (TIL) to fight solid tumors and blood cancers.
United States of America
IOVA
United States of America
IOVA
France
IPN
Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.
Sweden
IRLAB
Sweden
IRLAB
Develops and commercializes therapies for GI diseases like IBS-C and chronic constipation.
United States of America
IRWD
United States of America
IRWD
Developing antibody-based immunotherapies for oncology and rare diseases.
South Korea
086890
South Korea
086890
Develops novel oral & IV anti-infectives to combat multi-drug resistant pathogens.
United States of America
ITRM
United States of America
ITRM
Develops plant-based, non-opioid GI therapies for humans and animals.
United States of America
JAGX
United States of America
JAGX
Developing tumor-activated immunotherapies to treat cancer while minimizing systemic toxicities.
United States of America
JANX
United States of America
JANX
Pioneers regenerative medicine with tissue products, CDMO services, and research models.
Japan
7774
Japan
7774